Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-1968 in Anal High-Grade Squamous Intraepithelial Lesions
NCT03202992Phase 1Completed
- Sponsor
- Antiva Biosciences
- Start
- Aug 2017
- Primary completion
- Feb 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of abi-1968 in anal squamous intraepithelial lesion (ASIL) (10 arms), sponsored by Antiva Biosciences. Primary endpoint: Maximum Tolerated Dose at 84 days. Started Aug 2017; status: completed.
02
Drugs
abi-1968
03
Conditions
anal squamous intraepithelial lesion (ASIL)
Beyond the preview
Go deeper on NCT03202992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202992.